Avadel Pharmaceuticals is set to present groundbreaking data on its extended-release oral suspension, LUMRYZ™, at the upcoming SLEEP 2025 conference in Seattle. The presentations will include fourteen abstracts, with four dedicated to oral presentations, highlighting the drug’s significant impact on narcolepsy treatment both in clinical trials and real-world settings.
Impressive Study Results Demonstrate LUMRYZ’s Effectiveness
The interim analysis from the REFRESH study revealed that patients transitioning from twice-nightly oxybate to once-nightly LUMRYZ experienced meaningful reductions in excessive daytime sleepiness (EDS). Participants achieved median Epworth Sleepiness Scale (ESS) scores within the normal range after 13 weeks of treatment. Additionally, post-hoc analyses from the REST-ON trial indicated that LUMRYZ did not exacerbate the apnea-hypopnea index (AHI), ensuring that its efficacy is maintained without compromising respiratory health.
Patient Experiences Highlight Benefits of Once-Nightly Dosing
Real-world data from the REFRESH study illustrated that switching to LUMRYZ not only improved sleepiness symptoms but also enhanced overall patient compliance by simplifying dosing regimens. Approximately half of the 67 participants, including both oxybate-naïve and experienced users, reported significant improvements in sleep quality and daily functioning, emphasizing the drug’s practicality and patient-centered approach.
– LUMRYZ participants showed a median ESS score reduction to normal levels.
– No worsening of AHI was observed across all dosage groups.
– Patients experienced fewer hypnagogic and hypnopompic hallucinations compared to placebo.
– Long-term tolerability remained high, with only 4% discontinuing due to adverse events.
LUMRYZ stands out as a pivotal treatment option for narcolepsy, addressing both nocturnal and daytime symptoms with a simplified dosing schedule. Its approval by the FDA as the first once-at-bedtime oxybate underscores its innovation in improving patient adherence and quality of life. The data presented at SLEEP 2025 not only affirm LUMRYZ’s clinical benefits but also highlight its safety profile, making it a valuable addition to narcolepsy management strategies.
<a href="https://investors.avadel.com/news-releases/news-release-details/avadel-pharmaceuticals-present-new-data-lumryztm-sodium-oxybate”>Source
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
